Colesevelam HCl: A non-systemic lipid-altering drug

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 5, 2003, Pages 779-790

  Bays, Harold ^b   Dujovne, Carlos ^a  

^a RADIANT RESEARCH   (United States)

^b Louisville Metabolic and Atherosclerotic Research Center   (United States)

Author keywords

Bile acid; Bile acid sequestrant; Cholesterol; Cholestyramine; Colesevelam HCl; Colestipol; High density lipoprotein; Low density lipoprotein; Polymer; Resin

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; DIGOXIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; METOPROLOL; MEVINOLIN; MUSCLE ENZYME; NICOTINIC ACID; PHYTOSTEROL; PYRROLE DERIVATIVE; QUINIDINE; RESIN; RETINOL; SIMVASTATIN; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; WARFARIN;

CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; DYSLIPIDEMIA; FLUSHING; GASTROINTESTINAL DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; LIVER TOXICITY; METABOLIC DISORDER; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NONHUMAN; PRESCRIPTION; PRURITUS; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT;

ALLYLAMINE; ANIMALS; ANTILIPEMIC AGENTS; CHILD; CLINICAL TRIALS; DRUG INTERACTIONS; EXPERT TESTIMONY; FEMALE; HALF-LIFE; HUMANS; HYPERCHOLESTEROLEMIA;

EID: 0037797108     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/eoph.4.5.779.22219     Document Type: Review

References (38)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA (2001) 285(19):2486-2497.
2. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. Lipid research clinics program. JAMA (1984) 251:351-364.
3. GOTTO AM: Contemporary diagnosis and management of lipid disorders, 2nd edn (1999-2000). Handbooks in Healthcare Co.
4. BLANKENHORN DH, NESSIM SA, JOHNSON RL, SANMARCO ME, AZEN SP, CASHIN-HEMPHILL L: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA (1987) 257(23):3233-3240.
5. CASHIN-HEMPHILL L, MACK WJ, POGODA JM, SANMARCO ME, AZEN SP, BLAKENHORN DH: Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4 year follow-up. JAMA 264(23):3013-3017.
6. BROWN BG, ZHAO XQ, CHAIT A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. (2001) 345(22):1583-1592.
7. KANE JP, MALLOY MJ, PORTS TA, PHILLIPS NR, DIEHL JC, HAVEL RJ: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA (1990) 264:3007-3012.
8. DONOVAN JM, STYPINSKI D, STILES MR, OLSON TA, BURKE SK: Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc. Drugs Ther. (2000) 14:681-690.
9. HEIDELBAUGH JJ, RION RJ: Diagnosis and management of lipid disorders. Clin. Fam. Pract. (2001) 3(4):757-780.
10. NEZASA Y, TADAO A, KIMURA K, TAKAICHI M, INAZAWA K, KOIKE M: Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor in rat. Xenobiotica (2002) 32(8):715-727.
11. BAYS HE, DUJOVNE CA: Drug interactions of lipid-altering drugs. Drug Saf. (1998) 19(5):355-371.
12. THOMPSON PD, CLARKSON P, KARAS RH: Statin-associated myopathy. JAMA (2003) 289:1681-1690.
13. BALLANTYNE CM, CORSINI A, DAVIDSON MH et al.: Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med. (2003) 163:553-564.
14. BAYS HE: Ezetimibe. Expert Opin. Investig. Drugs (2002) 11(11):1587-1604.
15. ALDRIDGE MA, MATTHEW KI: Colesevelam hydrochloride: a novel bile acid-binding resin. Ann. Pharmacother. (2001) 35:898-907.
16. DIETSCHY JM: Theoretical considerations of what regulates low density lipoprotein and high density lipoprotein cholesterol. Am. J. Clin. Nutr. (1997) 65(Suppl. 5):1581S-1589S.
17. SPADY DK, DIETSCHY JM: Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea pig, rabbit, hamster, and rat. J. Lipid Res. (1983) 24:303-315.
18. DIETSCHY JM, TURLEY SD, SPADY DK: Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J. Lipid Res. (1993) 34(10):1637-1659.
19. BAYS HE: Existing and investigational combination drug therapy for high-density lipoprotein cholesterol Am. J. Cardiol. (2002) 90(Suppl.):30K-43K.
20. JOLLEY CD, WOOLLETT LA, TURLEY SD, DIETSCHY JM: Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-1 concentration. J. Lipid Res. (1998) 39:2143-2149.
21. HELLER DP, BURKE SK, DAVIDSON DM, DONOVAN JM: Absorption of colesevelam hydrochloride in healthy volunteers. Ann. Pharmacother. (2002) 36:398-403.
22. STEINMETZ KL: Colesevelam hydrochloride. Am. J. Health-Syst. Pharm. (2002) 59:932-939.
23. DAVISDSON MH, DILLON MA, GORDON B et al.: Colesevelam hydrochloride (Cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med. (1999) 159:1893-1900.
24. AVORN J, MONETTE J, LACOUR A et al.: Persistence of use of lipid-lowering medications: a cross national study. JAMA (1998) 279(18): 1458-1462.
25. DAVIDSON MH, DICKLIN MR, MAKI KC, KLEINPELL RM: Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent. Expert Opin. Investig. Drug (2000) 900:2663-2671.
26. HUNNINGHAKE D, INSULL W, TOTH P, DAVIDSON D, DONOVAN JM, BURKE SK: Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis (2001) 158:407-416.
27. KNAPP HH, SCHROTT H, MA P et al.: Safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am. J. Med. (2001) 110:352-360.
28. BAYS HE, WEISS S, GAGNE C et al.: Ezetimibe added to ongoing statin therapy for treatment of primary hypercholesterolemia. Oral contributions. J. Am. Coll. Cardiol. (2002) 39(Suppl. 5A):833-834.
29. GAGNE C, BAYS HE, WEISS SR et al.: For the Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. (2002) 90(10):1084.
30. MCKENNEY J: Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction. Am. J. Cardiol. (2002) 90(10B):8K-20K.
31. GRUNDY SM: Alternative approaches to cholesterol-lowering therapy. Am. J. Cardiol. (2002) 90(10):1135-1138.
32. DAVIDSON MH: Combination therapy for dyslipidemia: safety and regulatory considerations. Am. J. Cardiol. (2002) 90(10B):50K-60K.
33. DUJOVNE CA: Side effects of statins: hepatitis versus 'transaminitis' myositis versus 'CPKitis'. Am. J. Cardiol. (2002) 89(12):1411-1413.
34. PHILLIPS PS, HAAS RH, BANNYKH S et al.: The scripps mercy clinical research center statin-associated myopathy with normal creatine kinase levels Ann. Intern. Med. (2002) 137:581-585.
35. GRUNDY SM: Can statins, cause chronic low-grade myopathy? Ann. Intern. Med. (2002) 137:617-618.
36. BAYS HE, DUJOVNE CA, MCGOVERN ME et al.: Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am. J. Cardiol. (2003) 91:667-672.
37. INSULL W, TOTH P, MULLICAN W et al.: Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized control trial. Mayo Clin. Proc. (2001) 76(10):971-982.
38. DAVIDSON MH, DILLON MA, GORDON B et al.: Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med. (1999) 159(16):1893-1900.